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Coronary artery disease is the main cause of death worldwide and accelerated by increased
plasma levels of cholesterol-rich low-density lipoprotein particles (LDL). Circulating PCSK9
contributes to coronary artery disease by inducing lysosomal degradation of the LDL receptor
(LDLR) in the liver and thereby reducing LDL clearance. Here, we show that liver heparan
sulfate proteoglycans are PCSK9 receptors and essential for PCSK9-induced LDLR degra-
dation. The heparan sulfate-binding site is located in the PCSK9 prodomain and formed by
surface-exposed basic residues interacting with trisulfated heparan sulfate disaccharide
repeats. Accordingly, heparan sulfate mimetics and monoclonal antibodies directed against
the heparan sulfate-binding site are potent PCSK9 inhibitors. We propose that heparan
sulfate proteoglycans lining the hepatocyte surface capture PCSK9 and facilitates subsequent
PCSK9:LDLR complex formation. Our findings provide new insights into LDL biology and
show that targeting PCSK9 using heparan sulfate mimetics is a potential therapeutic strategy
in coronary artery disease.
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Increased level of plasma low-density lipoprotein (LDL) cho-lesterol is considered a key predictor for the development ofcoronary artery disease (CAD), which is the main cause of
death in the world. The primary choice of medication is statins,
and these are among the most commonly prescribed drugs
worldwide. Statins inhibit endogenous cholesterol synthesis and
concomitantly increase the expression of the low-density lipo-
protein receptor (LDLR) in hepatocytes1, resulting in increased
uptake of LDL cholesterol particles from the circulation by
LDLR-mediated endocytosis. LDL is subsequently degraded in
lysosomes and cholesterol is recovered for use in the hepatocyte
or conversion to bile acids while LDLR recycles to the cell surface.
Unfortunately, a considerable number of patients show insuffi-
cient response and do not reach the desired levels in plasma LDL
cholesterol2. Statins also increase the expression and secretion of
proprotein convertase subtilisin/kexin type 9 (PCSK9) in hepa-
tocytes3, 4. PCSK9 is structurally related to the proprotein con-
vertases but proteolytically inactive due to tight association
between the prodomain and the catalytic domain5. PCSK9 binds
LDLR on the surface of hepatocytes and triggers its degradation
in lysosomes thereby counteracting the beneficial effects of statins
at the posttranslational level. Accordingly, inhibition of the
PCSK9:LDLR interaction efficiently reduces plasma LDL choles-
terol, and the first two humanized antibodies blocking the LDLR-
binding site in PCSK9 recently received final clinical approval for
treating patients suffering from hypercholesterolemia6–8. How-
ever, it remains a mystery how the soluble monomeric protein
PCSK9 dramatically can change the cellular trafficking route of
the single-pass transmembrane receptor LDLR from recycling
to lysosomal degradation9, 10. Furthermore, the PCSK9:LDLR
binding constant is in the range of 170–628 nM11, 12 while the
PCSK9 plasma concentration is around 6 nM13, rendering it
unlikely that circulating PCSK9 binds LDLR directly at normal
physiological concentrations. In addition, PCSK9 targets LDLR in
the liver but not in, e.g., steroid hormone-producing tissues,
which also express high levels of LDLR, suggesting the require-
ment of a liver-specific co-receptor5, 14, 15.
The hepatocyte surface is covered with heparan sulfate pro-
teoglycans (HSPG) that are known to play important physiolo-
gical roles in several aspects of lipoprotein metabolism including
endocytosis of bound ligands16. Heparan sulfate is composed of
repeating disaccharide units consisting of glucuronic acid or
iduronic acid (IdoA), which can be O-sulfated, and N-acetyl
glucosamine (GlcN), which can be both O-sulfated and
N-sulfated, in an apparently specific and cell type-dependent
manner17. Heparin is a highly sulfated variant of heparan sulfate
obtained as a heterogeneous specie typically from porcine entrails
or equine lungs, and is the biopharmaceutical produced at the
largest scale worldwide due to its potent anticoagulant activity17.
In the present study, we observed that the amino acid sequence of
the PCSK9 prodomain contains a cluster of basic residues in
agreement with consensus sequences for interaction with
HSPG17, 18. We further find that these are essential for PCSK9
activity in vitro and in vivo and propose a model in which HSPG
capture and present PCSK9 to LDLR at the hepatocyte surface.
Accordingly, antibodies directed against the HSPG-binding site,
heparin or heparan sulfate mimetics are PCSK9 inhibitors and
may serve as a potential treatment for CAD.
Results
PCSK9 binds HSPG. We examined the electrostatic surface of
PCSK9 and identified a putative heparin-binding site composed
of six surface-exposed basic residues located in the PCSK9 pro-
domain. The binding site is formed by arginine (R) residues at
position 93, 96, 97, 104, and 105 and histidine (H) at position
139, which docked with sulfate groups of a heparin penta-
saccharide (SANORG) (Fig. 1a, b). The site is found opposite to
the LDLR binding surface located in the inactive catalytic domain
of PCSK9 (Supplementary Fig. 1a). Placing heparin onto a co-
crystal structure of PCSK9 in complex with LDLR further sug-
gested that heparan sulfate binding allows subsequent PCSK9:
LDLR complex formation (Supplementary Fig. 1b). We next
treated human hepatocyte-derived HepG2 cells stably expressing
PCSK9 with heparinase I, which cleaves heparan sulfate GAG
chains between GlcN and IdoA, thereby removing cell surface
heparan sulfate. Indeed, treatment resulted in a marked reduction
in the intensity of surface PCSK9 staining (Fig. 1c). No decrease
was observed upon treatment with chondroitinase (Supplemen-
tary Fig. 2a). To exclude that PCSK9 cell surface binding was
inhibited in an unspecific manner by heparinase-generated
heparan sulfate fragments, we first treated cells with heparinase
then thoroughly washed the cells, and subsequently incubated
them with purified PCSK9 on ice to prevent endocytosis. In this
experiment, heparinase treatment completely prevented PCSK9
cell surface binding, suggesting that HSPG are indeed PCSK9
receptors (Supplementary Fig. 2b). To study the direct interaction
between PCSK9 and heparan sulfate GAG chains, we employed
affinity chromatography using Sepharose beads covalently cou-
pled with heparin. Purified PCSK9 was retained on the heparin
column and eluted at a NaCl concentration of approximately 500
mM (Fig. 1d), confirming the interaction with heparin. We fur-
ther found that endogenous PCSK9 from conditioned media of
HepG2 cells also bound heparin (Supplementary Fig. 3a) and
showed similar elution profile as that of ApoE, a well-established
HSPG-binding protein19. To determine if the predicted HSPG-
binding motif in PCSK9 is responsible for heparin binding, we
cloned and expressed PCSK9 variants in which combinations of
the six amino acids were substituted for alanine (A) (Supple-
mentary Fig. 3b). All PCSK9 mutants were processed and secreted
in a similar manner from transfected Chinese Hamster Ovary
(CHO) cells (Supplementary Fig. 3c), indicating correct folding as
this is prerequisite for processing of proPCSK9 and subsequent
exit from the endoplasmic reticulum20. Substitution of combi-
nations of the six basic amino acids predicted in Fig. 1a, b,
including substitution of R93 to alanine (mut 1) or cysteine
(R93C), prevented binding (Fig. 1e and Supplementary Fig. 3d),
demonstrating that the site is responsible for the interaction with
heparin. Of note, PCSK9 R93C is a naturally occurring loss-of-
function variant21, 22. In contrast, substitution of other surface-
exposed basic residues positioned outside the predicted HSPG-
binding motif in PCSK9 (R165 and R167, mut 6) did not have
any major effect on heparin binding (Supplementary Fig. 3d, e).
HSPG binding is required for PCSK9-induced LDLR degradation.
We incubated HepG2 cells for 18 h with wild-type (WT) PCSK9
or a PCSK9 basic residue mutant lacking all six basic residues
(mut 5), and subsequently analyzed the LDLR levels by Western
blotting. We found that PCSK9 WT was approximately twice as
effective in inducing LDLR degradation compared to the PCSK9
mut 5 (Fig. 1f, g), suggesting that HSPG binding is critical in
PCSK9-induced LDLR degradation. Importantly, purified PCSK9
WT and PCSK9 mut 5 showed similar binding to the immobi-
lized extracellular domain of LDLR as determined using Biacore
(Supplementary Fig. 4a, b). We speculated that exogenously
added heparin could compete with cell surface HSPG for the
binding of PCSK9 and thereby prevent PCSK9:LDLR complex
formation. Using proximity ligation assay (PLA), abundant
surface clusters of PCSK9:LDLR complexes were observed in
non-permeabilized HepG2 cells (Fig. 1h). These were markedly
reduced both in numbers and intensity upon incubation with
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Fig. 1 PCSK9 cell surface binding and activity depend on HSPG. a A heparin pentasaccharide (SANORG, sticks) (PDB ID 1E03)61 docked at the electrostatic
surface (red negative; blue positive) of the HSPG-binding site in PCSK9 (PDB ID 3H42)26 with positively charged amino acids (R: arginine, H: histidine)
indicated. b Superposition of SANORG with PCSK9 (ribbon). c Non-permeabilized HepG2 cells-expressing PCSK9 (green) after treatment with or without
heparinase I. Nuclei were stained with Hoechst (blue). The experiment was repeated three times with similar results. d PCSK9 binding to heparin was
analyzed by affinity chromatography. e PCSK9 mutant with all six amino acids highlighted in a, b substituted for alanines (mut 5) showed complete loss of
heparin binding. Substitution of R93 alone for cysteine (R93C) also resulted in complete loss of heparin binding. f, g HepG2 cells incubated 18 h with WT
PCSK9 and PCSK9 mut 5 (10 nM of each, n= 4). h PLA analysis of non-permeabilized HepG2 cells showed that co-localization of LDLR and PCSK9 was
markedly reduced upon incubation of cells with heparin (500 µg/ml). The experiment was repeated three times with similar results. i, j LDLR levels in
HepG2 cells following incubation with heparin (500 µg/ml, 18 h, n= 4). k Heparin treatment resulted in accumulation of PCSK9 in the culture supernatant
(n= 3). l Effect of heparin on LDLR and PCSK9 mRNA levels. m Heparin (50 and 500 µg/ml) had no effect on the interaction between PCSK9 and LDLR in
a cell-free assay. A PCSK9 antibody (αPCSK9, 5 nM) directed against the LDLR-binding site is included as positive control (n= 3). Bar graphs show mean
values (n as indicated) with s.e.m. error bars. Statistical significance was evaluated using a two-tailed Student’s t-test. Scale bars are 10 µm. Supplementary
Fig. 10 shows uncropped gel images
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heparin (50 U/ml corresponding to approximately 500 µg/ml),
suggesting that PCSK9 binding to HSPG is instrumental in the
subsequent complex formation with cell surface LDLR. We found
that incubation of HepG2 cells with heparin (500 µg/ml for 18 h)
resulted in two to 3-fold higher level of LDLR protein (Fig. 1i, j).
A similar effect was observed with two therapeutic preparations
of low-molecular weight heparins (LMWH) as well as with
heparan sulfate but not with chondroitin sulfate (Supplementary
Fig. 5a, b). The increase in cellular LDLR in heparin-treated
HepG2 cells was dose-dependent and accompanied by a marked
increase in PCSK9 in the medium as determined using a PCSK9-
specific enzyme-linked immunosorbent assay (ELISA) (Fig. 1k).
The increase in cellular LDLR and extracellular PCSK9 induced
by heparin occurred at the post translational level as we observed
no change in mRNA, except for PCSK9 at the highest heparin
concentration (Fig. 1l). Nevertheless, 250 µg/ml heparin effec-
tively antagonized its activity as evident from approximately
2.5-fold increase in LDLR protein (Supplementary Fig. 5c) despite
the 2-fold increase in PCSK9 mRNA. Importantly, heparin did
not affect the direct binding of PCSK9 to immobilized LDLR in a
cell-free PCSK9 (biotinylated)-LDLR binding assay (Fig. 1m).
Heparin mimetics are PCSK9 inhibitors. Several molecules
mimicking the structure of heparin have been developed, seven of
which are currently in clinical use for a number of indications.
These are denoted heparin/heparan sulfate mimetics and belong
to diverse chemical classes, including various oligosaccharides,
oligonucleotides, and naphthalene derivatives23. We tested a
subset of mimetics for their ability to bind PCSK9 and increase
LDLR in HepG2 cells (Fig. 2a–d and Supplementary Fig. 5d, e).
The sulfated oligosaccharides dextran sulfate and pentosan sulfate
both bound directly to PCSK9 with affinity constants of 180 and
381 µM, respectively, as estimated using Microscale Thermo-
phoresis (MST), and resulted in dose-dependent increase in cel-
lular LDLR, reaching a plateau of around 400% compared to
control. The interaction was dependent on the presence of sulfate
groups as non-sulfated dextran showed no affinity for PCSK9.
The sulfated naphthalene derivative suramin, an antiparasitic
drug used against African sleeping sickness, resulted in up to
15-fold increase in LDLR and concomitantly increased uptake of
LDL in HepG2 cells (Supplementary Fig. 5f). Phosphorothioate
oligonucleotides are highly anionic and known to interact with
heparin-binding proteins24, 25. We therefore tested a modified
36-mer phosphorothioate oligodeoxycytidine (S-dC-36) and
found that it bound PCSK9 with a KD of 4.8 µM and showed
inhibitory effects at this concentration range. Thus, it appears that
a number of negatively charged compounds display inhibitory
activity toward PCSK9, and to further understand the
structure–activity relationship crystallographic data on a PCSK9:
heparin mimetic complex would be desirable. We noted that
dextran sulfate was a constituent of the crystallization buffer for
the crystal structure of PCSK9 in complex with a Fab fragment of
evolocumab26. In the PDB data set, we discovered electron den-
sity surrounding the α-helix constituting the HSPG-binding site,
which was 11-fold above the background level, and had not been
accounted for in the published structure. We solved the
remaining part of the structure and found it to encompass a
dextran sulfate disaccharide interacting with R93, R97, R104, and
H139 of PCSK9 (Fig. 3a–c, Supplementary Fig. 6 and Supple-
mentary Table 1). Taken together, these data suggest that the
number and positioning of negatively charged functional groups
of sulfated sugars and mimetics are critical determinants for their
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Fig. 2 Heparin mimetics are potent PCSK9 inhibitors. Structure of the heparin mimetics dextran sulfate (a), pentosan sulfate (b), suramin (c), and the
phosphorothioate oligonucleotide S-dC-36 (d) (R= SO3− or H). Binding curves and the dose-dependent effects on LDLR levels in HepG2 cells (n= 3–5,
bar graphs show mean values with s.e.m. error bars) are shown below each mimetic structure. Statistical significance was evaluated using a two-tailed
Student’s t-test. Summary of binding constants and representative LDLR Western blots are shown in Supplementary Fig. 5d, e
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PCSK9 binds trisulfated heparan sulfate disaccharide repeats.
The extracellular matrix and plasma membrane contain a wide
variety of negatively charged glycans such as HSPG and the
composition is highly tissue and cell type-dependent. To dissect
the specificity and selectivity of the interaction of PCSK9 with
negatively charged sugars, we analyzed PCSK9 binding to a gly-
can microarray consisting of immobilized synthetic extracellular
matrix glycans, including defined chain length and sulfation
patterns of heparan sulfate/heparin and the related glycosami-
noglycans keratan sulfate and dermatan sulfate (Supplementary
Table 2). Strikingly, PCSK9 showed a remarkable selectivity for
trisulfated heparan sulfate/heparin disaccharide repeats consisting
of [4)-α-GlcN-6,N-disulfate(1→ 4)-α-IdoA-2-sulfate-(1→] as
evident from the binding of the heparin oligos I and VII
encompassing three and two repeats, respectively (Fig. 4a–b and
Supplementary Table 2). A minimum of two repeats was required
for efficient binding as no binding was observed for heparin oligo
X consisting of only one repeat, and it is possible that the pre-
sence of additional repeats may further increase PCSK9 binding
to such heparin oligos. The requirement of sulfate groups at the
amino group of GlcN or of ester-linked sulfate groups at carbon 6
of GlcN and at carbon 2 of IdoA was also apparent by comparing
the binding to heparin oligos I, II, and III, demonstrating that
PCSK9 binding strictly requires repeating trisulfated dis-
accharides (Fig. 4a, b). Natural heparin with an average molecular
weight of 5 kDa was included in the array as a positive control.
Remarkably, the binding signal for heparin oligo I was several
folds higher than for natural heparin, which is a heterogeneous
mixture of variable chain length and sulfation pattern.
PCSK9 inhibitory antibodies directed at the HSPG-binding site.
We asked the question whether an antibody specifically directed
against the HSPG-binding surface in PCSK9 could have a similar
inhibitory effect as heparin and heparin mimetics. Thus, we
generated PCSK9 antibodies by DNA immunization of rats using
a construct encoding a rat chimeric protein encompassing the
human HSPG-binding sequence stretch (Fig. 5a). Polyclonal
antibodies that specifically recognized native human PCSK9 were
successfully generated from three rats (Fig. 5b) and these showed
a promising ability to increase LDLR in HepG2 cells (Fig. 5c).
Monoclonal antibodies (mAbs) were subsequently generated, and
a series of 12 inhibitory mAbs were obtained, which individually
provided an up to 2-fold increase in LDLR levels in HepG2 cells
(Fig. 5d, e). Of note, this magnitude is similar to the reported
effect of mAbs directed against the LDLR-binding site26, 27. We
next probed the 12 mAbs for their ability to immunoprecipitate
metabolically labeled PCSK9 mut 5 (Fig. 5f). Clones 1G8, 5E11,
and 8H4 showed no recognition of mut 5, showing that at least
one the six basic acids depicted in Fig. 1b is part of the epitope of
these PCSK9 inhibitory antibodies (Fig. 5f). Further analysis by





















Fig. 3 Structure of PCSK9 in complex with a dextran sulfate disaccharide. a Structure of dextran sulfate disaccharide on the electrostatic surface (blue:
positive; red: negative) of the pro-domain of PCSK9 (PDB ID: 5OCA) with amino acids indicated (H: histidine and R: arginine). b Side view of the binding
site containing conformation 1 of dextran sulfate with interacting residues indicated (Q: glutamine, T: threonine). c Simulated annealing Fc-Fo composite
omit map (positive density show in green and contoured at 3σ) of dextran sulfate in two alternative conformations (confirmations 1 (cyan) and 2 (magenta)).
Interacting residues of PCSK9 are indicated and show together with a simulated annealing 2Fc-Fo composite omit map (blue and contoured at 1σ)
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clones 1G8 and 5E11 critically depended on R96, R97, R104, and
R105 (Supplementary Fig. 7b). Finally, we found that mAb 5E11
increased the uptake of LDL in HepG2 cells to a similar extent as
evolocumab directed at the LDLR-binding surface (Fig. 5g).
Importantly, mAb 5E11 did not perturb the direct binding
between PCSK9 and LDLR in a cell-free assay (Supplementary
Fig. 7c).
PCSK9 activity in vivo requires HSPG binding. To study the
role of HSPG in PCSK9 activity in vivo, we tested the ability of
b
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Fig. 4 PCSK9 binding to synthetic glycans. a Dissection of the interaction between PCSK9 and extracellular matrix glycans (numbers refer to
Supplementary Table 2) using a synthetic glycan microarray. Natural heparin is included as a positive control. b The heparin structures immobilized in the
glycan microarray are shown. Structures interacting with PCSK9 contain repeats of [4)-α-GlcN-6,N-disulfate(1→ 4)-α-IdoA-2-sulfate-(1→]
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00568-7
6 NATURE COMMUNICATIONS | 8:  503 |DOI: 10.1038/s41467-017-00568-7 |www.nature.com/naturecommunications
tail vein-injected PCSK9 to downregulate LDLR with or without
prior injection of heparinase I. PCSK9 alone (10 µg, corre-
sponding to an initial concentration of approximately 68 nM)
resulted in approximately 90% decrease in LDLR levels after
60 min specifically in the liver but not in the adrenal gland
(Supplementary Fig. 8a, b). In contrast, injection of heparinase I
5 min before PCSK9 administration completely protected LDLR
from degradation, demonstrating that HSPG are instrumental
in PCSK9-induced LDLR degradation in vivo (Fig. 6a, b).
Heparinase treatment unmasks the antigenicity of syndecan-1,
a major liver HSPG (Supplementary Fig. 9), confirming the
effectiveness of the treatment (Fig. 6a). We subsequently tested if
heparinase releases and antagonizes endogenous PCSK9 and
found that heparinase injection resulted in approximately 30%
increase in plasma PCSK9 15 min later (Fig. 6c, d). Interestingly,
we observed a similar increase in plasma PCSK9 accompanied
by markedly increased liver LDLR and reduced total plasma















































































































































































































Fig. 5 Generation of inhibitory mAbs directed against the PCSK9 HSPG-binding site. a Rats were immunized with cDNA encoding a rat PCKS9 chimera
encompassing the human HSPG-binding site. The overall sequence identity between rat and human PCSK9 is 77%. b IP of radioactive-labeled PCSK9
(35S-PCSK9) using serum from three immunized rats. Preimmune serum is used as control. See full gel in Supplementary Fig. 7a. c LDLR levels in HepG2
cells following incubation with IgG from immunized animals compared to preimmune IgG (1 µg/ml). d mAbs were tested by IP. Fifteen mAbs specifically
precipitated radioactive-labeled PCSK9. e LDLR levels in HepG2 cells incubated with the individual mAbs (n= 3–5). Twelve individual mAbs showed a
significant and around 2-fold increase in LDLR, and were tested for binding to PCSK9 mut 5 by IP. f A polyclonal antibody was used as positive control
(R&D systems, AF3888). Three mAbs, including 5E11, failed to precipitate PCSK9 mut 5. g Uptake of fluorescently labeled LDL (DiI-LDL) in HepG2 cells
incubated with 100 nM PCSK9 alone (control) or in combination with 5E11 or evolocumab as indicated (n= 3). Bar graphs show mean with s.e.m. error bars.
Statistical significance was evaluated using a two-tailed Student’s t-test. Supplementary Fig. 10 shows uncropped gel images
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human heparanase (Hpa-tg)28, suggesting that HSPG binding is
critical for endogenous PCSK9 activity (Fig. 6e–h).
We further found that both heparin and suramin prevented
LDLR degradation as co-injection of heparin (500 µg) or suramin
(300 µg) with PCSK9 had a pronounced protective effect on liver
LDLR (Fig. 7a). In addition, a single injection of suramin alone
(50 mg/kg) significantly increased LDLR levels and reduced total
plasma cholesterol 18 h later specifically in WT mice but not in
PCSK9 knockout mice (Fig. 7b, c), suggesting that the effect is
indeed PCSK9-dependent. Protection of LDLR was also observed
upon co-injection of PCSK9 with mAb 5E11 (50 µg), showing
that directly targeting the HSPG site has inhibitory effect in vivo
(Fig. 7d, e). Furthermore, PCSK9 with mutated HSPG site (mut
5) was unable to induce LDLR degradation (Fig. 7f, g). Similarly,
while injection of PCSK9 WT significantly increased total
cholesterol in mice on Western type diet, no such effect was
observed by PCSK9 mut 5 (Fig. 7h), confirming that the HSPG
binding is active in vivo. Previous studies have proposed that the
clearance pathway for plasma PCSK9 is through LDLR14, 29. We
observed that plasma levels of injected PCSK9 mut 5 were
markedly increased compared to PCSK9 WT at the time points
analyzed (Fig. 7i) in line with reduced capture by HSPG and
reduced presentation to LDLR. Hence, these results indicate that
HSPG and LDLR may in fact cooperate in PCSK9 plasma
clearance.
Discussion
Our combined results lead us to propose a model (Fig. 8) in
which HSPG on the hepatocyte surface capture PCSK9 and
present it to the LDLR, hereby ensuring optimal conditions for
PCSK9:LDLR complex formation. The transmembrane HSPG of
the syndecan type undergo ligand-induced clustering in the
plasma membrane30–32 and mediate both clathrin-dependent and
independent endocytosis of bound ligands30, 31, 33–35. Hence, it is
tempting to speculate that sorting motifs in the cytoplasmic tail of
syndecans could participate in directing the PCSK9:LDLR com-
plex to lysosomes for degradation.
The HSPG-binding site is located in the PCSK9 prodomain in
a region not previously implicated mechanistically in LDLR
degradation and found on the opposite surface of the structure





































































































































Fig. 6 Enzymatic removal of liver heparan sulfate releases PCSK9 and ablates its activity. a, b Infusion of heparinase I prior to the injection of PCSK9 (10 µg)
completely inhibits PCSK9-induced degradation of LDLR. Western blot of representative samples is shown in a and quantification of LDLR in b (control
n= 7, PCSK9 n= 6, heparinase n= 5, heparinase/PCSK9 n= 5). Heparinase treatment unmasks the antigenicity of the major liver HSPG syndecan-1
(middle panel). Beta-actin is used as loading control (lower panel). c Heparinase I treatment leads to an increase in plasma PCSK9 as measured by ELISA 15
min after injection (control n= 6, heparinase n= 6). dWestern blot (representative samples) of liver syndecan-1 is used as control of heparinase injection.
Beta-actin is shown as loading control. e–h Transgenic mice with constitutive expression of human heparanase (Hpa-tg) (n= 7) have increased plasma
PCSK9 (e), increased liver LDLR (f, g), and reduced plasma cholesterol (h) compared to control WT mice (n= 6). Bar graphs show mean with s.e.m. error
bars. Statistical significance was evaluated using a two-tailed Student’s t-test. Supplementary Fig. 11 shows uncropped gel images
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inactive catalytic domain of PCSK9. HSPG binding involves six
basic residues one of which is R93 (Fig. 1a, b and Supplementary
Fig. 3d). Interestingly, individuals harboring a PCSK9 LOF var-
iant in which R93 is substituted for cysteine (R93C) display highly
significant reductions in LDL cholesterol and are protected
against CAD21, 22. The molecular mechanism behind this PCSK9
LOF variant has so far been unknown, but loss of HSPG binding
as suggested by Fig. 1e may explain the low-LDL phenotype of
R93C carriers.
The expression profile of HSPG encoding genes in the liver and
the chemical properties of liver heparan sulfate GAG chains are
unique16, potentially providing the basis for the tissue-specific
activity of PCSK9 as observed in Supplementary Fig. 8. As such,




































































































































































































































Fig. 7 Inhibition of PCSK9:HSPG interaction protects LDLR in vivo. a LDLR is protected in mice co-injected with PCSK9 (10 µg) and heparin (500 µg) or
suramin (300 µg) compared to mice injected with PCSK9 alone (control n= 15, PCSK9 n= 10, PCSK9/heparin n= 7, PCSK9/suramin n= 3). b, c A single
injection of suramin (50mg/kg) increased liver LDLR levels (b) and reduced total plasma cholesterol (c) 18 h later in WT mice (control n= 5, suramin
n= 8) but not in PCSK9 KO mice (control n= 5, suramin n= 7). d, e Co-injection of PCSK9 (10 µg) with mAb 5E11 (50 µg) protects the LDLR from
degradation (control n= 4, PCSK9 n= 7, PCSK9/mAb 5E11 n= 6). Representative blot is shown. f, g PCSK9 with mutated HSPG-binding site (mut 5)
(10 µg) is ineffective in inducing LDLR degradation (n= 3 of each). h PCSK9 but not PCSK9 mut 5 significantly increases total cholesterol in mice fed
Western-type diet 6 h post injection (control n= 25, PCSK9 n= 12, PCSK9 mut 5 n= 9). i Injected PCSK9 mut 5 remained in circulation for a prolonged
time compared to PCSK9 WT in line with reduced capture by HSPG and clearance by LDLR. Bar graphs show mean with s.e.m. error bars. Statistical
significance was evaluated using a two-tailed Student’s t-test. Supplementary Fig. 11 shows uncropped gel images
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as negatively charged compared to other tissues and are enriched
in trisulfated disacharides36; the optimal structure for PCSK9
binding (Fig. 4a, b). Interestingly, highly sulfated HSPG on the
hepatocyte surface are also employed by Plasmodium sporozoites
during malaria infection and by both dengue and hepatitis C
virus. Similarly to PCSK9, the interaction with heparan sulfate is
mediated by specific binding motifs formed by basic residues on
parasite and virus surface proteins37–39, suggesting that this
mechanism for liver-specific targeting is conserved in biology.
As example, malaria infection is initiated by an Anopheles
mosquito bite at the skin, injecting Plasmodium sporozoites
that subsequently migrate on low-sulfated HSPG such as
those found in skin and on the endothelial surface until
highly sulfated HSPG on hepatocytes activates sporozoite
invasion37.
Liver heparan sulfate is covalently attached to two major
classes of core proteins, syndecans (1–4) and glypicans (1–6).
Isolated mouse hepatocytes express syndecan-1, syndecan-2, and
syndecan-4 and glypican-1 and glypican-440. Similar expression
profile of syndecans was also observed in whole human and
mouse liver by analyzing data from the two transcriptional
databases Unigene (www.ncbi.nlm.nih.gov) and GTEx (www.
gtexportal.org) (Supplementary Fig. 9). However, only glypican-3
is expressed in high levels in human but not in mouse liver
according to Unigene. This expression was not confirmed by the
GTEx data set and none of the other glypicans appeared to be
expressed to any notable extent. Sulfation of heparan sulfate
attached to one of these core proteins occurs in patterns gener-
ated by the cooperation of several different sulfotransferases. In
the case of four key sulfotransferases Ndst (1–4)41, a previous
study using semi-quantitative PCR reported Ndst-1, Ndst-2, and
Ndst-3 expression in human liver42. Ndst-1 and Ndst-2 but not
Ndst-3 expression in human liver was confirmed by the Unigene
and GTEx data sets, while mouse liver was found to express
Ndst-1 and Ndst-3 but not Ndst-2 (Supplementary Fig. 9). Future
studies should address the specificity of the interaction between
PCSK9 and the individual syndecans and glypicans, how these
contribute to PCSK9-induced sorting of LDLR to lysosomes, and
further which sulfotransferases are critical for generating the
PCSK9 binding pattern in heparan sulfate chains in mouse and
human cells.
Considering our findings, it is highly interesting that five
clinical trials using long-term treatment with low-dose heparin at
sub therapeutic amounts with respect to anticoagulation, all have
reported marked reductions in cardiac events and deaths
although the mechanism for this has remained unclear43–48.
Furthermore, other studies have found that both acute and long-
term heparin and dextran sulfate administration in humans
reduces LDL and total cholesterol levels, respectively49–54. At a
stage where patients throughout the world are about to be treated
with humanized antibodies directed against the PCSK9:LDLR
complex, the present study provides important insight into the
biological mechanism of PCSK9 activity. It also opens up a venue
for future development of small molecule heparin mimetics as
PCSK9 inhibitors.
Methods
Cell culture. Human hepatocyte-derived cells (HepG2) and human embryonic
kidney cells (HEK293) were cultured at 37 °C in a humidified atmosphere con-
taining 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented
with 10% fetal calf serum, penicillin (50 U/ml), and streptomycin (50 µg/ml).
CHO-K1 cells were cultured in HyClone-CCM5 media (Thermo) supplemented
with penicillin (50 U/ml) and streptomycin (50 µg/ml). Cells were transfected using
Fugene6 transfection reagent (Promega). CHO-K1 cells stably transfected with
PCSK9 cDNA were maintained in 400 μg/ml G418, and stably transfected HepG2
cells in 1 µg/ml puromycin (InvivoGen). All cells were obtained from ATCC and





Fig. 8 Model depicting the role of HSPG in PCSK9 activity in the hepatocyte. The model shows a hepatocyte and how LDLR in the absence of PCSK9
mediates endocytosis of bound LDL cholesterol particles followed by lysosomal degradation of LDL, while LDLR recycles to the cell surface. HSPG mediates
the capture of PCSK9 and its subsequent presentation to LDLR thereby directing LDLR itself to lysosomes for degradation. In the model, we have depicted
HSPG as syndecan but based on the present data we cannot exclude that it may also be a glypican
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DNA constructs and recombinant protein expression. The peptide sequence of
PCSK9 used in this study is identical to GenBank acc. no. CAC38896.1. The PCSK9
coding sequence was ligated into the pCpGfree-vitroNmcs expression vector and
transformed into the E. coli strain GT115 encoding the pir gene (Invivogen).
Mutants were created by successive overlapping PCR and inserted into the pCpG-
vitroNmcs vector. Plasmids were sequenced by Eurofins. WT PCSK9 and derived
mutants were expressed transiently in CHO-K1 cells. CHO-K1 cells stably trans-
fected with PCSK9 were adapted to growth in suspension in Hybridoma-SFM
medium (GIBCO) and then expanded in Celline CL 350 Bioreactor flasks (Integra)
or in triple layer flasks (Thermo).
Purification of recombinant PCSK9. Growth media from PCSK9-expressing
CHO cells were dialyzed overnight against 20 mM Tris-HCl pH 7.6 and 75 mM
KCl. The dialyzed sample was loaded on a 1 ml MonoQ column (GE Healthcare)
equilibrated in buffer Q-A (20 mM Hepes pH 7.6, 75 mM KCl, and 10% glycerol).
Bound PCSK9 was eluted with a gradient from 0 to 100% buffer Q-B (20 mM
Hepes pH 7.6, 500 mM KCl, and 10% glycerol). Fractions containing PCSK9 were
pooled and further purified on a 24 ml Superdex 200 INCREASE column (GE
Healthcare) equilibrated in phosphate buffered saline (PBS). Fractions containing
PCSK9 were pooled and concentrated to 1 mg/ml (based on absorbance at 280 nm)
using a centrifugation filter (Amicon Ultra-4 10,000MW cut-off). The con-
centration of PCSK9 was subsequently determined by ELISA (R&D Systems,
DPC900).
Surface plasmon resonance analysis. Surface plasmon resonance analysis was
performed on a Biacore 3000 equipped with CM5 sensor chips activated. LDLR
extracellular domain (Biaffin GmbH & Co KG, LDR-H5224) was immobilized to a
density of 60 fmol/mm2 in 10 mM sodium acetate, pH 4.0, and remaining coupling
sites were blocked with 1M ethanolamine, pH 8.5. Samples, PCSK9 WT and mut 5,
were injected at 5 μl/min at 25 °C in 10 mM HEPES, pH 7.4, 150 mM NaCl, 1.5
mM CaCl2, 1 mM EGTA, and 0.005% Tween 20 (CaHBS). Binding was expressed
in relative response units; the difference in response between the immobilized
protein flow cell and the corresponding control flow cell. Kinetic parameters were
determined using BIAevaluation 4.1.
Heparin affinity chromatography. PCSK9 was loaded onto a 5 ml HiTrap
Heparin HP column (GE Healthcare) in PBS. The column was connected to an
Äkta Prime and washed with 5 column volumes of 10 mM NaH2PO4 (pH 7.4).
PCSK9 was eluted using a linear gradient of 10 mM NaH2PO4 (pH 7.4) and 2M
NaCl and fractions were analyzed by SDS-PAGE. Based on the measured con-
ductivity, the elution profile was transformed to a function of NaCl concentration
using the transformation coefficient 0.065 mS/mM NaCl. In a different experiment,
conditioned media from HepG2 cells or CHO cells transfected with PCSK9 var-
iants of interest were incubated with Heparin Sepharose CL-6B beads (GE
Healthcare) in 10 mM NaH2PO4 (binding buffer). Following overnight incubation
on a rotor at 4 °C, beads were washed in binding buffer before batch elution of
heparin-bound proteins in increasing concentration of NaCl. PCSK9 in the input,
flow through, and elution fractions was determined by Western blotting.
Antibodies. The following antibodies were used for Western blotting: anti-LDLR
(Abcam ab52818, 1:1000), anti-GAPDH (Sigma Aldrich G8795, 1:2000), anti-beta
actin (Sigma A5441, 1:5000), anti-PCSK9 (R&D Systems AF3985, 1:1000), anti-
syndecan-1 (R&D AF3190, 1:1000), and immunostainings: anti-PCSK9 (R&D
Systems AF3888, 2 µg/ml), and fluorescent secondary antibodies (Invitrogen).
Detailed information on our use of primary antibodies can be found in the pAb-
mAbs database www.pAbmAbs.com deposited by Camilla Gustafsen or Ditte
Olsen.
Production of PCSK9 inhibitory antibodies. Antibodies raised against the HSPG-
binding domain in PCSK9 were produced by Aldevron Freiburg, Germany. Rats
were immunized with DNA encoding chimeric rat PCSK9 containing the human
HSPG-binding domain. Serum samples were tested for PCSK9 binding by IP and
their ability to increase LDLR levels in HepG2 cells. mAb-producing hybridoma
clones were obtained by fusion of spleen lymphocytes with myeloma cells and
subsequent single-cell subcloning of antibody-producing cells.
Western blotting. Proteins were separated by SDS-PAGE (NuPAGE 4–12%
Bis-Tris; Invitrogen) and transferred to nitrocellulose membranes using iBlot Gel
Transfer Stacks (Invitrogen). Membranes were blocked in 5% skimmed milk
in TBST (0.05 M Tris-base, 0.5 M NaCl supplemented with 0.1% Tween-20),
and incubated with primary antibodies diluted in blocking buffer overnight.
Membranes were washed three times in 0.5% skimmed milk in TBST and incu-
bated with horseradish peroxidase (HRP)-conjugated secondary antibodies. Fol-
lowing a final washing step, proteins were visualized with the ECL plus Western
blotting detection system (GE Healthcare) using a Fuji film LAS4000 system. See
Supplementary Figs. 10 and 11 for uncropped Western blot images.
Microscale thermophoresis. Equilibrium-binding affinities between PCSK9 and
ligands (suramin, dextran sulfate 5000, dextran 5000, pentosan sulfate, and S-dC-
36) were assessed using MST55. PCSK9 was labeled using the MO-L003 Monolith
Blue-NHS labeling kit (NanoTemper Technologies) and a labeling efficiency of 1:1
molar ratio of protein to dye was achieved. PCSK9 was applied at a final con-
centration of 100 nM. The unlabeled binding partner was titrated in 1:1 dilutions
(in PBS + 0.05% Tween-20) where the highest concentrations were 15.4 mM for
suramin, 2.3 mM for dextran sulfate 5000, 2.3 mM for dextran 5000, 16.3 mM for
pentosan sulfate, and 250 µM for S-dC-36. MST measurements were performed in
standard-treated capillaries (NanoTemper Technologies) on a Monolith NT.115
instrument (NanoTemper Technologies) using 20% LED and 80% MST power.
Laser on and off times were 5 and 35 s, respectively. Negative controls were per-
formed using 100 nM of labeled PCSK9 in MST buffer in all 16 capillaries under
the same conditions as mentioned above. Binding curves were obtained from the
temperature-jump phase at 80% MST power for suramin, dextran sulfate 5000, and
S-dC-36; and from the thermophoresis + temperature-jump phase at 80% MST
power for pentosan sulfate. For each binding partner, the sigmoidal dose-response
curves were fitted with GraphPad Prism 6 to yield an average KD value. As
fluorescence quenching of PCSK9 was observed in the presence of high con-
centrations of suramin, a denaturation test was performed by pre-treating PCSK9
with 10% SDS and then heating the samples for 15 min at 90 °C prior to analysis on
the MST apparatus. This eliminated the quenching effect, indicating that the
fluorescence quenching of PCSK9 under non-denaturing conditions was due to an
actual ligand-binding event.
PCSK9-induced LDLR degradation in vitro. HepG2 cells have several morpho-
logical and functional features of human hepatocytes, including endogenous
expression of LDLR and PCSK9. We continuously confirmed this prior to per-
forming experiments. HepG2 cells were seeded at a density 250,000 cells per well in
12-well plates. After overnight incubation, the media was replaced with fresh media
containing one of the following components: purified PCSK9 variants, PCSK9
mAbs, heparin (Leo Pharma, 585679), glycosaminoglycans: heparan sulfate (Sigma,
H7640) or chondroitin sulfate (Sigma, C9819), LMWH: Fragmin (Pfizer, 085423)
and Innohep (Leo Pharma, 595570), heparin mimetics: suramin sodium (Sigma,
S2671), dextran sulfate sodium (Sigma, D4911), pentosan sodium polysulfate
(Anthropharm Ireland limited, 003192), and phosphorothioate oligodeoxycytidine
36-mer (S-dC-26) (Sigma). Cells were harvested and lysed following 18 or 24 h
incubation and LDLR levels were assessed by Western blotting and quantification
by densitometry.
LDL uptake assay. HepG2 cells were seeded at 25,000 cells/96 well. Following
overnight incubation, the medium was changed to DMEM without supplements
for an additional 24 h. Cells were subsequently incubated with or without PCSK9
(100 nM) and with or without PCSK9 inhibitors 5E11 (0.1–1.0 µM), evolocumab
(0.1–1.0 µM) and suramin (200 µg/ml) in serum-free medium for 4 h at 37 °C
before addition of 5 µg/ml DiI-LDL (Thermo Fisher Scientific) or BODIPY-LDL
(Thermo Fisher Scientific) for 4 h at 37 °C. Wells were washed with PBS and
cellular uptake of fluorescence was evaluated using an EnSpire Alpha Plate Reader
(Perkin Elmer) at excitation/emission 552/573 nm (DiI) or 515/520 nm (BODIPY).
After overnight incubation of plates at −80 °C, the number of cells/well was
quantified using the CyQuant Cell Proliferation Assay (Thermo Fisher Scientific),
according to the manufacturer’s protocol.
Mouse experiments. Unless otherwise stated, in vivo experiments were performed
with 10–12-week-old male BALB6/cJRj (Janvier Labs). Mice were injected intra-
venously (tail vein) with 0.9% saline (vehicle control), PCSK9 (10 µg) with or
without heparin (50 units), suramin (300 µg), or mAb 5E11 (50 µg) in a rando-
mized order by an investigator blinded to the content. Heparinase I (30 U) (Sigma
Aldrich/H2519) was administrated though a tail vein catheter 5 min before injec-
tion of PCSK9 (10 µg). During heparinase infusion, mice were lightly anaesthetized
with isoflurane continuously administered through a mask. One hour post injec-
tion, mice were sacrificed and tissue samples were collected and snap frozen.
Proteins were extracted from liver and adrenal gland and the concentration was
determined (Bicinchoninic Acid Assay (Sigma)). Equal amounts of samples (30 µg
protein) were analyzed by Western blotting. In a different experiment, suramin (50
mg/kg) was injected in BALB6/cJRj and PCSK9-deficient control mice (B6:129S6-
Pcsk9tm1Jdn/J, Jackson Laboratory)56, and tissue samples were collected 18 h after
injection. Hpa-tg mice overexpressing human heparanase driven by a β-actin
promoter in a BALB/c genetic background were generated by breeding with WT
Balb/C from Harlan Laboratories28. Plasma and liver tissue samples were obtained
from 8-weeks male animals. All animal experiments were carried out according to
the institutional ethical guidelines of Aarhus University and approved by the
Danish Animal Experiments Inspectorate under the Ministry of Justice.
Plasma cholesterol measurement. Male BALB6/cJRj mice (Janvier Labs) were fed
ad libitum western-type diet (D12079B, Research Diet) for 4 weeks before injection
of WT or mutant PCSK9 (mut 5) (10 µg/25 g mouse). Total cholesterol levels in Li-
Heparin plasma sampled prior (control) and six hours post injection were assessed
using Cholesterol CHOD-PAP reagent (Roche/Hitachi). Plasma cholesterol levels
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in suramin-injected BALB6/cJRj and PCSK9 KO mice, as well as in Hpa-tg mice,
were determined in a similar manner.
Immunoprecipitation. Antibodies from 1 µl immune or preimmune rat serum or
500 µl conditioned media from mAb-producing hybridoma clones were immobi-
lized on GammaBind beads (GE Healthcare), and used for precipitation (3 h at
4 °C) of 35S human PCSK9 from conditioned media of metabolically labeled
HEK293 transiently transfected with PCSK9 as described previously9. Following
three washes in TBS containing 0.1% Triton X100, precipitated proteins were
eluted by boiling samples in NUPAGE sample buffer supplemented with 20 mM
dithioerythritol, separated by SDS-PAGE, and visualized by phosphorimaging.
Crystal structure of PCSK9:dextran sulfate. PCSK9 was previously
co-crystalized with a Fab fragment of evolocumab in a crystallization cocktail
composed of 0.1 M Tris (pH 8.3), 0.2 M sodium acetate, 10–15% PEG4000, and
3–6% dextran sulfate sodium salt (Mr: 5000)26. The coordinates and corresponding
structure factors from the Protein Databank (PDBid: 3H42) was used to examine
the structure. A difference electron density (Fo-Fc) map revealed a peak 11 σ above
the mean density near the alkaline helix (residues 92–104) in the pro-domain of
PCSK9 which was not accounted for in the deposited model. Next a simulated
annealing composite omit map was created to remove model bias. The omit map
showed additional unaccounted electron density near the alkaline helix (Fig. 3c and
Supplementary Fig. 6). A disaccharide of dextran sulfate was placed into this
electron density and the structure was refined by iterative turns of model building
in Coot57, followed by subsequent refinement using phenix.refine58. To confirm
that the improved agreement between model and data was due to the inclusion of
dextran sulfate, we added the refined position of dextran sulfate only to the
deposited model and calculated its refinement statistics (Supplementary Table 1).
The dextran sulfate disaccharide was placed in two alternative orientations in the
electron density. The occupancy and real-space correlation coefficient of the two
conformations were 40/74% and 30/73% for conformation 1 and conformation 2,
respectively. The overall B-factor for conformations 1 and 2 was 78 Å3. For
comparison, the surrounding residues showed similar B-factors, i.e., 79 Å3 for
R104, 61 Å3 for R97, 62 Å3 for R93, and 64 Å3 for H139. For simplification, con-
formation1 with the highest occupancy is shown in Fig. 3a, b.
Extracellular matrix glycan microarray. Extracellular matrix glycan microarray,
including synthetic oligosaccharides of heparan sulfate/heparin, keratan sulfate,
dermatan sulfate, and 5 kDa natural heparin (Santa Cruz) (Supplementary
Table 2), were prepared as described previously using 250 µM spotting
solution59, 60. After spotting, the microarray slides were incubated overnight in a
humid chamber, followed by three washing steps with water and quenching with
50 mM ethanolamine solution, pH 9, for 1 h at 50 °C to remove the remaining
reactive groups. Slides were washed three times with water, blocked at room
temperature for 1 h with 1% (w/v) BSA in PBS, pH 7.4 and dried by centrifugation
(5 min, 300 × g). PCSK9 (25 µg/ml) were incubated overnight at 4 °C diluted in 1%
(w/v) BSA-PBS in a humid chamber. After three washing steps with 0.1% (v/v)
Tween-PBS, an incubation with preincubated 0.1 µg/ml humanized anti-PCSK9
mAb and 5 µg/ml goat anti-human IgG Alexa Fluor 647 (Life Technologies) diluted
in 1% BSA-PBS was performed for 1 h at room temperature. Slides were washed
three times with 0.1% (v/v) Tween-PBS, rinsed once with water and dried by
centrifugation. For data acquisition slides were scanned with GenePix 4300
microarray scanner (Molecular Devices, Sunnyvale, CA, USA) by exciting Alexa
Fluor 647 at 635 nm. Photomultiplier tube values were set to reveal scans free of
saturation. Median fluorescence values were determined with GenePix Pro 7 soft-
ware (Molecular Devices).
Immunofluorescence. HepG2 cells stably transfected with PCSK9 were seeded at
50,000 cells per coverslip and incubated overnight before addition of Heparinase I
(Sigma Aldrich/H2519) or Chondroitinase (Sigma Aldrich/C3667) in PBS (0.0002
U/ml) or PBS alone. Cells were incubated for 1 h at 37 °C, before fixation in 4%
paraformaldehyde and immunostaining of non-permeabilized cells with primary
and secondary antibodies. Nuclei were visualized with Hoechst dye (Sigma
Aldrich). Images were acquired on a Zeiss LSM780. In a different experiment,
HepG2 cells were incubated with Heparinase I before washing with 3× PBS and
incubation with PCSK9 (500 nM) on ice. Following binding of PCSK9 cells were
fixed and non-permeabilized cells were subjected to immunofluorescence staining.
Proximity ligation assay. The PLA (Duolink®II, Olink Bioscience) was performed
according to manufacturer’s protocol using anti-PCSK9 (R&D Systems/AF3888),
and anti-LDLR (Abcam/ab52818) as primary antibodies. PCSK9 and LDLR located
within 30 nm from each other are visualized by oligonucleotide-conjugated sec-
ondary antibodies that hybridize with circle-forming oligonucleotides thereby
priming rolling circle amplification. The amplified DNA is visualized by addition of
complementary fluorescently labeled oligonucleotides.
Molecular docking of SANORG. Coordinates for the heparin pentasaccharide
(SANORG) were extracted from the crystal structure of α-antithromin III (PDB ID
1E03)61. PCSK9 (PDB ID 3H42)26 and heparin were prepared for docking, i.e.,
adding Gasteiger charges and hydrogens, with AutoDocktools62. Docking was
performed with Autodock Vina63 using a grid with dimensions of 43 × 46 × 40
centered at R97. During docking, residues R93, R96, R97, R104, R105, and H139
were considered flexible. Ligand poses were scored according to their calculated
free energy and the pose with lowest free energy while also fulfilling the restraint to
contain sulfate groups coordinated by H139, and R93, R97 and R104 was chosen.
PyMol (Schrödinger, LLC) was used for modeling and visualizing structures.
Enzyme-linked immunosorbent assay. The PCSK9 concentration in conditioned
media of HepG2 cells was measured using Human (DPC900) Quantikine ELISA kit
from R&D Systems, according to the manufacturer’s protocol. The ELISA kit was
also used to assess the concentration of purified PCSK9 WT and mut 5 used for
in vitro and in vivo experiments.
Quantitative RT-PCR. RNA extraction from HepG2 cells was performed using
NucleoSpin RNA preparation kit (Macherey-Nagel), following cDNA synthesis
from 0.5 µg RNA template by iScript™ cDNA synthesis kit (BIORAD). Real-time
PCR was performed with iQ SYBR® Green supermix and iTaq™ polymerase using
the following primers to detect transcripts of LDLR (forward primer 5′-ACGGC
GTCTCTTCCTATGACA-3′, reverse primer 5′-CCCTTGGTATCCGCAAC
AGA-3′), PCSK9 (forward primer 5′-CCTGGAGCGGATTACCCCT-3′, reverse
primer 5′-CTGTATGCTGGTGTCTAGGAGA-3′), and GAPDH (forward primer
5′-ACAACTTTGGTATCGTGGAAGG-3′, reverse primer 5′-GCCATCACGCCA
CAGTTTC-3′).
PCSK9/LDLR-binding assay. The interaction between PCSK9 and LDLR in the
presence of heparin was analyzed using a PCSK9-(biotinylated)-LDLR-binding
assay kit (BPS Bioscience), according to the manufacturer’s protocol. Briefly,
microtiter plate wells coated with LDLR extracellular domain were incubated with
biotinylated PCSK9 in the presence of heparin (5 or 50 U/ml), 5 nManti-PCSK9
(BPS Bioscience #71207), evolocumab (Amgen), or mAb 5E11. Following washing,
wells were incubated with HRP-labeled streptavidin and binding of PCSK9 to
the LDLR extracellular domain was assessed by addition of HRP substrate and
evaluation of signal using a chemiluminescence microplate reader.
Statistics. Results were evaluated using Student’s t-test and error bars indicate
standard error of mean (s.e.m.). All data were normal distributed and the variance
was similar among groups. p-values are indicated by asterisks: *p< 0.05, **p< 0.01,
***p< 0.001, ****p < 0.0001, and *****p< 0.00001.
Data availability. The coordinates of the PCSK9:dextran sulfate structure have
been deposited in the Protein Data Bank (PDB ID: 5OCA). Antibody testing data
has been posted on www.pabmabs.com by Camilla Gustafsen or Ditte Olsen. The
data sets generated in the current study are included in this published article or are
available from the corresponding authors upon reasonable request.
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